OKYO Pharma Ltd ADR
Price & Volume
Stats
See more52W Range | $0.90-$3.34 |
Market Cap | $76.7M |
Shares Short | 21,304 |
Financials
See moreRevenue (12 Mos) | $0 |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | -$4.8M |
Diluted EPS | -$0.12 |
News
See moreYahoo Finance • 17 days ago
OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain
Yahoo Finance • 3 months ago
OKYO Pharma stock maintains Buy rating at H.C. Wainwright on positive trial data
Yahoo Finance • 3 months ago
OKYO Pharma reports results from Urcosimod trial
Yahoo Finance • 3 months ago
OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain
About
CEO | Dr. Gary S. Jacob Ph.D. |
Address | 14/15 Conduit St, London, United Kingdom, W1S 2XJ |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 4 |
